Albers, LJ, Reist, C, Helmeste, D et al (1996) Paroxetine shifts imipramine metabolism. Psychiatry Research; 59: 189–96.
Adli, M., Baethge, C, Heinz, A et al (2005) Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed?
European Archives of Psychiatry and Clinical Neuroscience; 255: 387–400.
Alamo, C, López-Muñoz, F, Rubio, G et al (2007) Combined treatment with reboxetine in depressed patients with no response to venlafaxine: a 6-week follow-up study. Acta Neuropsychiatrica; 19: 291–6.
Aydemir, O, Taskin, EO, Deveci, A (2005) Mirtazapine augmentation in treatment-resistant major depressive disorder: an open label, six week trial. European Neuropsychopharmacology; 15 (suppl): 401–2.
Baker, CB, Tweedie, R, Duval, S et al (2003) Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis. Depression and Anxiety; 17: 1–9.
Bauer, M, Dopfmer, S (1999) Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. Journal of Clinical Psychopharmacology; 19: 427–34.
Benazzi, F (1998) Serotonin syndrome with mirtazapine–fluoxetine combination. International Journal of Geriatric Psychiatry; 13: 495–6.
Berlanga, C, Ortega-Soto, HA (1995) A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. Journal of Affective Disorders; 34: 187–92.
Bertschy, G, Ragama-Pardos, E, Muscionico, M et al (2005) Trazodone addition for insomnia in venlafaxine-treated, depressed inpatients: a semi-naturalistic study. Pharmacological Research; 51: 79–84.
Bondolfi, G, Lissner, C, Kosel, M et al (2000) Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. Interntaional Journal of Neuropsychopharmacology; 3: 55–60.
Boyer, EW, Shannon, M (2005) The serotonin syndrome. New England Journal of Medicine; 352: 1112–20.
Carpenter, LL, Yasmin, S, Price, LH (2002) A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biological Psychiatry; 51: 183–8.
Conus, P, Bondolfi, G, Eap, CB et al (1996) Pharmacokinetic fluvoxamine–clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. Pharmacopsychiatry; 29: 108–10.
Davidson, J, McLeod, M, Yone-Law, B et al (1978) A comparison of electroconvulsive therapy and combined phenelzine–amitriptyline in refractory depression. Archives of General Psychiatry; 35: 639–42.
Debonnel, G, Gobbi, G, Turcotte, J et al (2000) Effects of mirtazapine, paroxetine and their combination: a double-blind study in major depression. European Neuropsychopharmacology; 10: 252.
Dodd, S, Horgan, D, Malhi, GS et al (2005) To combine or not to combine? A literature review of antidepressant combination therapy. Journal of Affective Disorders; 89: 1–11.
Fava, M, Rosenbaum, JF, McGrath, PJ et al (1994) Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. American Journal of Psychiatry; 151: 1372–4.
Fava, M, Alpert, J, Nierenberg, A et al (2002) Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. Journal of Clinical Psychopharmacology; 22: 379–87.
Gillman, PK (2007) Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. British Journal of Pharmacology; 151: 737–48.
Gómez Gómez, JM, Perramón Teixidó, C (2000) Combined treatment with venlafaxine and tricyclic antidepressants in depressed patients who had partial response to clomipramine and imipramine. Journal of Clinical Psychiatry; 61: 285–9.
Gonul, AS, Akdeniz, F, Donat, O et al (2003) Selective serotonin reuptake inhibitors combined with venlafaxine in depressed patients who had partial response to venlafaxine: four cases. Progress in Neuro-Psychopharmacology and Biological Psychiatry; 27: 889–91.
Hannan, N, Hamzah, Z, Akinpeloye, HO et al (2007) Venlafaxine–mirtazapine combination in the treatment of persistent depressive illness. Journal of Psychopharmacology; 21: 161–4.
Husain, SS, Kevan, IM, Linnell, R et al (2004) Electroconvulsive therapy in depressive illness that has not responded to drug treatment. Journal of Affective Disorders; 83: 121–6.
Jacobsen, FM (1990) Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study. Journal of Clinical Psychiatry; 51: 298–302.
König, F, Wolfersdorf, M (1997) Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression. Pharmacopsychiatry; 30: 93–6.
Lane, R, Baldwin, D (1997) Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. Journal of Clinical Psychopharmacology; 17: 208–21.
Lauritzen, L, Clemmesen, R, Klysner, R et al (1992) Combined treatment with imipramine and mianserin. A controlled pilot study. Pharmacopsychiatry; 25: 182–6.
Levitt, AJ, Joffe, RT, Kamil, R et al (1999) Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination?
Journal of Clinical Psychiatry; 60: 613–6.
López-Muñoz, F, Alamo, C, Rubio, G et al (2007) Reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors. Pharmacopsychiatry; 40: 14–9.
Lydiard, RB, Anton, RF, Cunningham, T (1993) Interactions between sertraline and tricyclic antidepressants. American Journal of Psychiatry; 150: 1125b–6b.
Maes, M, Vandoolaeghe, E, Desnyder, R (1996) Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. Journal of Affective Disorders; 41: 201–10.
McGrath, PJ, Stewart, JW, Fava, M et al (2006) Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. American Journal of Psychiatry; 163: 1531–41.
Medhus, A, Heskestad, S, Tjemsland, L (1994) Mianserin added to tricyclic antidepressants in depressed patients not responding to a tricyclic antidepressant alone. Nordic Journal of Psychiatry; 48: 355–8.
National Institute for Health and Clinical Excellence (2004) Depression: Management of Depression in Primary and Secondary Care. NICE.
Nelson, JC, Mazure, CM, Jatlow, PI et al (2004) Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biological Psychiatry; 55: 296–300.
Nierenberg, AA, Keck, PE Jr (1989) Management of monoamine oxidase inhibitor-associated insomnia with trazodone. Journal of Clinical Psychopharmacology; 9: 42–5.
Nierenberg, AA, Cole, JO, Glass, L (1992) Possible trazodone potentiation of fluoxetine: a case series. Journal of Clinical Psychiatry; 53: 83–5.
O'Brien, S, McKeon, P, O'Regan, M (1993) The efficacy and tolerability of combined antidepressant treatment in different depressive subgroups. British Journal of Psychiatry; 162: 363–8.
Oefele, KV, Grohmann, R, Ruther, E (1986) Adverse drug reactions in combined tricyclic and MAOI therapy. Pharmacopsychiatry; 19: 243–4.
Otte, W, Birkenhager, TK, van den Broek, WW (2003) Fatal interaction between tranylcypromine and imipramine. European Psychiatry; 18: 264–5.
Pampallona, S, Bollini, P, Tibaldi, G et al (2004) Combined pharmacotherapy and psychological treatment for depression: a systematic review. Archives of General Psychiatry; 61: 714–9.
Papakostas, GI, Shelton, RC, Smith, J et al (2007) Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. Journal of Clinical Psychiatry; 68: 826–31.
Papakostas, GI, Fava, M, Thase, ME (2008) Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biological Psychiatry; 63: 699–704.
Prapotnik, M, Waschgler, R, König, P et al (2004) Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine?
International Journal of Clinical Pharmacology and Therapeutics; 42: 120–4.
Prospero-Garcia, KA, Torres-Ruiz, A, Ramirez-Bermudez, J et al (2006) Fluoxetine–mirtazapine interaction may induce restless legs syndrome: report of 3 cases from a clinical trial. Journal of Clinical Psychiatry; 67: 1820.
Razani, J, White, KL, White, J (1983) The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. Archives of General Psychiatry; 40: 657–61.
Rojo, JE, Ros, S, Agüera, L et al (2005) Combined antidepressants: clinical experience. Acta Psychiatrica Scandinavica Supplementum; 428: 25–31.
Rubio, G, San, L, López-Muñoz, F et al (2004) Reboxetine adjunct for partial or nonresponders to antidepressant treatment. Journal of Affective Disorders; 81: 67–72.
Shekelle, PG, Woolf, SH, Eccles, M et al (1999) Clinical guidelines: developing guidelines. BMJ; 318: 593–6.
Steinberg, R, Jost, C, Weess, HG et al (1994) Combination of tricyclic antidepressants with moclobemide or tranylcypromine – outcome data in therapy resistant MD. Neuropsychopharmacology; 10: 62.
Tanghe, A, Steeman, J, Bollen, G et al (1997) Moclobemide and amitriptyline, alone or in combination, in therapy resistant depression. Human Psychopharmacology: Clinical and Experimental; 12: 509–10.
Weilburg, JB, Rosenbaum, JF, Biederman, J et al (1989) Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. Journal of Clinical Psychiatry; 50: 447–9.
Westermeyer, J (1991) Fluoxetine-induced tricyclic toxicity: extent and duration. Journal of Clinical Pharmacology; 31: 388–92.
White, K, Razani, J, Simpson, G (1982) Combined MAOI-tricyclic antidepressant treatment: a controlled trial. Psychopharmacology Bulletin; 18: 180–1.
Young, J, Lader, M, Hughes, W (1979) Controlled trial of trimipramine, monoamine oxidase, and combined treatment in depressed outpatients. BMJ; 2: 1315–17.